Skip to main content

Dr. Li is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Li's full profile

Already have an account?

  • Office

    325 W 15th St
    New York, NY 10011
    Phone+1 212-367-1870
    Fax+1 212-604-6038

Education & Training

  • Westchester Medical Center
    Westchester Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
  • Rutgers Health/Newark Beth Israel Medical Center
    Rutgers Health/Newark Beth Israel Medical CenterResidency, Internal Medicine, 1996 - 1999
  • Shandong Medical University
    Shandong Medical UniversityClass of 1984

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1999 - 2026
  • NJ State Medical License
    NJ State Medical License 2002 - 2025
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Neoadjuvant Chemotherapy in Local‐Regionally Advanced Nasopharyngeal Carcinoma: A National Cancer Database Analysis  
    Babak Givi, Kenneth Hu, Moses Tam, Naamit K Gerber, S Peter Wu, Anna Lee, Zujun Li, The Laryngoscope

Press Mentions

  • Perlmutter Cancer Center’s Head & Neck Cancer Doctors Help People with Cancer Look Better, Experience Fewer Side Effects
    Perlmutter Cancer Center’s Head & Neck Cancer Doctors Help People with Cancer Look Better, Experience Fewer Side EffectsMay 23rd, 2022
  • Prevalence of Psychological Symptoms in Community-Dwelling Chinese American Patients with Chronic Cancer Pain
    Prevalence of Psychological Symptoms in Community-Dwelling Chinese American Patients with Chronic Cancer PainFebruary 2nd, 2021
  • Maxinovel‘S Orally Active PD-L1 Inhibitor Demonstrating Similar Efficacy to PD-L1 Antibody Durvalumab
    Maxinovel‘S Orally Active PD-L1 Inhibitor Demonstrating Similar Efficacy to PD-L1 Antibody DurvalumabApril 19th, 2019
  • Join now to see all